About Drugnews
Drugnews is a biotech and pharmaceutical business-analysis media platform.
We do not stop at headlines. We interpret whether clinical evidence, company strategy, licensing activity, manufacturing risk, and capital-market signals can change the business value of a company or a sector.
Editorial Standard
How we write
We prioritize clinical data, regulatory progress, company disclosures, licensing terms, and verifiable sources.
Mechanism, efficacy, safety, CMC, competition, payment structure, and market positioning are interpreted together.
We try to distinguish disclosed facts, reasonable inference, and unresolved uncertainty.
Website articles preserve titles, dates, canonical URLs, references, and citation guidance for long-term use.
What readers can expect
Drugnews serves biotech investors, industry professionals, BD and IR teams, and readers learning how to interpret biotech companies.
Company research
Products, platforms, competitors, clinical milestones, cash runway, and market positioning organized into trackable company judgment.
Clinical and CMC risk
Endpoints, safety, manufacturing, supply chain, and regulatory signals interpreted as commercial evidence.
BD and licensing
Upfront payments, milestones, royalties, options, territory rights, and deal risk explained through buyer and seller incentives.
Valuation and capital markets
rNPV, SOTP, peak sales, peer comparisons, and capital-market sentiment used to explain why assets are repriced.
Collaboration boundaries
Drugnews may work with companies on feature articles, interviews, IR narratives, event recaps, and company-service content. Collaboration must be based on public information, company-approved disclosure, and professional research frameworks.
No non-public material information
Collaboration content should not include undisclosed material information, insider information, or unauthorized details.
No market-performance promise
Our content work aims to improve understanding and communication quality. It does not promise share-price, volume, fundraising, or investor behavior outcomes.
Professional judgment remains
Even in collaboration content, Drugnews keeps basic fact-checking, risk disclosure, and industry context.